IDEAYA Biosciences, Inc. IDYA IDE574 — External Clinical Development Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by IDEAYA Biosciences, Inc. in its filing.
Tagged under the XBRL concept idya:ExternalClinicalDevelopmentExpenses.
The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about IDEAYA Biosciences, Inc.'s ide574 — external clinical development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is IDEAYA Biosciences, Inc.'s IDE574 — external clinical development expenses?
- IDEAYA Biosciences, Inc. (IDYA) reported IDE574 — external clinical development expenses of $3.05M in Q1 2026.
- What does IDE574 — external clinical development expenses mean?
- This metric represents the total external costs incurred specifically for the clinical advancement of the IDE574 therapeutic candidate, including payments to contract research organizations, clinical trial sites, and laboratory service providers. It serves as a key indicator of the capital intensity and development velocity of this specific pipeline asset. Monitoring these expenses helps investors assess the company's resource allocation toward its precision medicine portfolio and the progress of clinical milestones.